Oramed Pharmaceuticals (NASDAQCM:ORMP) is developing proprietary Protein Oral Delivery (POD™) technology for the delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently approaching a Phase 2 trial under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.
Oramed in the News
November 26, 2013: FastCompany: The race for insulin pills
November 11, 2013: SEEKING ALPHA - Oramed's Success In Type 1 Diabetes Could Solve Novo Nordisk's Problems
October 9, 2013: REUTERS - Pharma's David and Goliath in race to produce insulin pill
For more of Oramed in the news, please click here.